University of Basel researchers demonstrate Angle's Parsortix system can capture over 99% of circulating tumor cell clusters from blood samples, enabling breakthrough metastasis prevention research.

The National University of Singapore and Cerner Enviza have collaborated on Project Golden Years, investigating evolving attitudes towards dementia prevention in Singapore through real-world qualitative research.

Late-breaking results from the CLEAR OASIS 9 trial reveal that colchicine failed to reduce cardiovascular events after myocardial infarction despite lowering inflammatory markers.

The Research Institute of McGill University Health Centre (RI-MUHC) has initiated a global Phase 1 clinical trial for Actinium-225, a novel treatment targeting metastatic prostate cancer. This trial, led by Dr. Ramy Saleh, aims to evaluate the safety and tolerability of Actinium-225, which targets the prostate-specific membrane antigen (PSMA) to kill cancer cells while sparing healthy organs. The study represents a significant advancement in precision medicine for patients who have exhausted other treatment options.

Cordis has initiated the SELUTION Global Coronary Registry, which will track real-world outcomes of their sirolimus-eluting balloon in up to 10,000 patients worldwide for five years.

Uppsala University researchers have discovered that CAR molecules can transfer from engineered CAR-T cells to other T cells through a process called trogocytosis, challenging previous understanding of this mechanism.

NIH-funded preclinical research demonstrates that uric acid treatment significantly improved sensorimotor function and survival rates in rodents 30 days after ischemic stroke.

Ernexa Therapeutics has established ErnexaTX2, a Texas-based subsidiary to support the preclinical development of ERNA-101, its lead cell therapy program for ovarian cancer.

University of California, San Diego has received IRB approval to conduct independent clinical trials of Nexalin's HALO Clarity device for treating mild traumatic brain injury and PTSD.

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

New research reveals that more than 10.6 hours of daily sedentary behavior significantly increases risk of heart failure and cardiovascular mortality, even among those meeting exercise guidelines.

Oragenics Inc. terminated its President's employment agreement, as disclosed in a recent SEC filing, marking a significant leadership change.

Two new trials in the UK will investigate the benefits of cannabis-based medicines for children and adults with refractory epilepsy, addressing a critical need for evidence-based treatment options.

Research at University of Kentucky Markey Cancer Center reveals that the word 'trial' in clinical trials carries negative connotations, particularly among minority populations, impacting participation rates.

University of Manchester and The Christie receive £5.9m grant from Cancer Research UK to simulate radiotherapy trials using AI.

Researchers at Duke University have developed an HIV vaccine candidate that effectively guides immune cells to produce broadly neutralizing antibodies.

Cure Rare Disease secures a $5.69 million grant from CIRM to develop an innovative antisense oligonucleotide therapy for SCA3, a rare neurodegenerative disorder currently lacking treatment options.

International researchers launch NANORAY-312 trial investigating hafnium metal therapy combined with radiation as a novel treatment approach for head and neck cancer patients unsuitable for cisplatin treatment.

Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth.

RAPT Therapeutics has commenced a Phase 2a clinical trial to assess RPT193, an oral, once-daily monotherapy, for treating moderate-to-severe asthma.